Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell …
N Aiko, T Shimokawa, K Miyazaki, Y Misumi, Y Agemi… - BMC cancer, 2018 - Springer
Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
Management of CNS metastases in patients with EGFR mutation-positive NSCLC
Central nervous system (CNS) metastases are a frequent and severe complication
associated with epidermal growth factor receptor (EGFR)-mutated non-small cell lung …
associated with epidermal growth factor receptor (EGFR)-mutated non-small cell lung …
Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
A comparison between first-, second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer and …
S Caponnetto, O Cantale, A Friedlaender… - Journal of Molecular …, 2021 - mdpi.com
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
BX Wang, W Ou, XY Mao, Z Liu, HQ Wu… - Clinical Neurology and …, 2017 - Elsevier
Objective Brain metastases remain lethal in lung cancer patients. The impacts of epidermal
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present …
C Proto, M Imbimbo, R Gallucci, A Brissa… - … lung cancer research, 2016 - ncbi.nlm.nih.gov
Lung cancer is one of the major causes of cancer related mortality worldwide. Brain
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases
Z Song, Y Zhang - Journal of Clinical Neuroscience, 2014 - Elsevier
Survival and treatment options are limited for patients with brain metastases arising from non-
small cell lung cancer (NSCLC). We evaluated erlotinib and gefitinib as salvage treatments …
small cell lung cancer (NSCLC). We evaluated erlotinib and gefitinib as salvage treatments …
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase …
J Kashima, Y Okuma, M Miwa, Y Hosomi - Medical Oncology, 2016 - Springer
Brain metastases (BM) is one of the most crucial distant metastases in patients with non-
small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) …
small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) …
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs …
MX Li, H He, ZH Ruan, YX Zhu, RQ Li, X He, BH Lan… - BMC cancer, 2017 - Springer
Background Central nervous system (CNS) brain metastasis of advanced non-small cell
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
[HTML][HTML] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
K Dong, W Liang, S Zhao, M Guo, Q He… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background It has been confirmed that epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …